Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations.
Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Alimera Sciences’ management team has a strong track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry and are dedicated and focused to making Alimera a leading ophthalmic pharmaceutical company.
Our team has demonstrated expertise through the extensive development and commercialization of ophthalmic products.
6120 Windward Parkway, Suite 290
30005 United States